Compare Neurocrine Biosciences Inc (NBIX) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs RLX Technology Inc — how do they compare? Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B), while RLX Technology Inc trades at $2.03 (market cap $2.52B). The key difference: Neurocrine Biosciences Inc is far larger — about 6.9× RLX Technology Inc's market cap, and RLX Technology Inc pays a 4.85% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | RLX | |
|---|---|---|
Market Cap | $17.40B | $2.52B |
Sector | Health | Technology |
52-Week High | $180.55 | $2.73 |
52-Week Low | $123.10 | $1.79 |
Enterprise Value | $16.49B | $1.15B |
Dividend Yield | — | 4.85% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
